Bosulif Tab (bosutinib), Pfizer’s new treatment for Philadelphia chromosomal-positive chronic myeloid leukemia, has won domestic approval.

The Ministry of Food and Drug Safety said Friday that it had approved three doses (100mg, 400mg, and 500 mg) of Pfizer Korea’s Bosulif (bosutinib) tablets.

The Philadelphia chromosome is created by the interchange of some genes on chromosomes Nos. 9 and 22. Chronic myeloid leukemia is mostly caused by the Philadelphia chromosome. It is a blood cancer in which abnormal blood cells multiply excessively and slowly progress.

According to the ministry, Bosulif prevents excessive proliferation of abnormal blood cells by inhibiting the expression of abnormal proteins activated by the Philadelphia chromosome,

Its indications approved in Korea are adult patients newly diagnosed with chronic Philadelphia chromosome-positive chronic myelogenous leukemia and chronic myelogenous leukemia positive for Philadelphia chromosomes in chronic, accelerated, and acute periods resistant or intolerant to previous therapies.

“We will do our best to expand treatment options for patients by enabling the swift supply of drugs with proven safety and efficacy based on regulatory and scientific expertise,” the ministry said.